LGND
Ligand Pharmaceuticals Incorporated
Stock
$302.96+0.22 (+0.07%)Close Oct 2, 2026
- Stock-based compensation, 2025
- $47M
- YoY, 2025
- +14.0%
- 5-year CAGR
- +8.8%
- 10-year CAGR
- +14.2%
Stock-based compensation
Stock-based compensation by fiscal year
| Period | Stock comp | YoY |
|---|---|---|
| 2025 | $47M | +14.0% |
| 2024 | $41M | +59.6% |
| 2023 | $26M | −57.3% |
| 2022 | $60M | +55.4% |
| 2021 | $39M | +26.2% |
| 2020 | $31M | +25.3% |
| 2019 | $25M | +17.6% |
| 2018 | $21M | −16.3% |
| 2017 | $25M | +31.9% |
| 2016 | $19M | +51.7% |
| 2015 | $12M | +10.5% |
| 2014 | $11M | +98.9% |
| 2013 | $5.7M | +39.3% |
| 2012 | $4.1M | +21.4% |
| 2011 | $3.4M | +44.1% |
| 2010 | $2.3M | −30.9% |
| 2009 | $3.4M | — |